Program Description:
Keeping up with new data and applying up-to-date information in treating patients with cancer has been identified by healthcare professionals as the biggest challenge in the treatment of hematologic and oncologic disorders. Featuring a faculty of internationally recognized experts, the CTCA REVIEW online webcasts highlight cutting-edge research and clinical studies presented during recent American Society of Hematology (ASH) and American Society of Clinical Oncology (ASCO) annual meetings. As highlights from the annual CTCA REVIEW, a live review course hosted by the Cancer Treatment Centers of America, the course material has been divided into two online activities. This online activity highlights Hematology/Oncology content. A second online activity highlights Oncology/Solid Tumor content.
INTENDED AUDIENCE:
The CTCA REVIEW Online Webcasts are intended for healthcare providers involved in the care of hematology and oncology patients, including medical oncologists, hematologists, radiation oncologists, radiologists, pathologists, oncology fellows, resident trainees, primary care providers, nurse practitioners, physician assistants, nurses, chiropractors, naturopathic physicians, and pharmacists.
MEDIUM:
Internet
Activity Objectives:
After participating in each CTCA REVIEW Online Webcast, learners should be able to:
- Interpret new and emerging data presented at the ASH and ASCO annual conferences
- Incorporate newer evidence- based data to assess the care of their patients with cancer
- Incorporate knowledge gained into appropriate management strategies to improve outcomes in patients with cancer
- Utilize current standards of care for patients with cancer
|
Credits
|
Type
|
Accreditation Statement
|
Designation Statement
|
|
1.50
|
AMA PRA Category 1 Credit(s)TM
|
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Dannemiller and Athena Education Group. Dannemiller is accredited by the ACCME to provide continuing medical education for physicians.
|
Dannemiller designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
|
|
1.50
|
CE for Nurses
|
Dannemiller is a provider approved by the California Board of Registered Nursing, Provider Number 4229 for 1.5 contact hours. RNs outside California must verify with their licensing agency for approval of this course.
|
|
Faculty:
Maintenance Therapy in Multiple Myeloma: When, What, and Why?
Kenneth C. Anderson, MD
Chief, Lipper Myeloma Center and Lebow Institute for Myeloma Therapeutics
Dana-Farber Cancer Institute
Kraft Family Professor of Medicine
Harvard Medical School
Boston, MA
Chronic Lymphocytic Leukemia: Treatment Challenges and Recent Advances
Susan M. O’Brien, MD
Ashbel Smith Professor
Chief, Section of Acute Lymphocytic Leukemia
Department of Leukemia
University of Texas MD Anderson Cancer Center
Houston, TX
Relapsed/Refractory Multiple Myeloma: Treatment and Its Expectations
James R. Berenson, MD
Medical and Scientific Director
Institute for Myeloma and Bone Cancer Research
West Hollywood, CA
Role of PET Scan – Interim and Prior to Transplant – in Lymphoma
Pamela Crilley, DO
Hematology and BMT
Cancer Treatment Centers of America
Philadelphia, PA
New Trends of Hematopoietic Cell Transplantation for Non-Hodgkin’s Lymphoma
Istvan Redei, MD
Director of the Stem Cell Transplant and Cell Therapy Program
Cancer Treatment Centers of America
Zion, IL
Myeloproliferative Diseases, including CMML: Update on Diagnosis, Genetics, and Treatment
Ayalew Tefferi, MD
Professor of Medicine and Hematology
Mayo Clinic
Rochester, MN
Smoldering and Newly Diagnosed Symptomatic Multiple Myeloma: Challenges in Selection of Frontline Therapy
Robert A. Kyle, MD
Professor of Medicine,
Laboratory Medicine & Pathology
Mayo Clinic
Rochester, MN
Chronic Myeloid Leukemia-Patterns of Failure with TKIs-What is Next?
Jerald P. Radich, MD
Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, WA
Lymphoma: Novel Targets, Agents, and Trials
Julie Vose, MD, MBA
Neumann M. and Mildred E. Harris Professor
Chief, Division of Hematology/Oncology
Professor of Medicine
Nebraska Medical Center
Omaha, NE
Disclosures:
Faculty
Kenneth C. Anderson, MD, has reported that he was a consultant/advisory board member for Bristol-Myers Squibb, Celgene, Merck, Millenium Pharmaceuticals, and Onyx Pharmaceuticals and a stockholder for Acetylon Pharmaceuticals and Oncopep.
James R. Berenson, MD, has reported that he was a speaker for Celgene, Millenium Pharmaceuticals, Novartis, and Onyx Pharmaceuticals, was a consultant/advisory board member for Celgene, Millenium Pharmaceuticals, Novartis, and Onyx Pharmaceuticals, and was an investigator for Celgene, Millenium Pharmaceuticals, Novartis, and Onyx Pharmaceuticals.
Pamela Crilley, DO, has reported no conflicts of interest.
Robert A. Kyle, MD, has reported that he was a speaker for Binding Site, and investigator for Bristol-Myers Squibb, Celgene, Johnson and Johnson, Keryx Biopharmaceuticals, Merck, Novartis, and Onyx Pharmaceuticals.
Susan M. O’Brien, MD, has reported that she was a speaker for The Medal Group, was a consultant/advisory board member for Bayer, Calistoga, Celgene, Cephalon, CLL Global Research Foundation, GlaxoSmithKline, MorphoSys, Pharmacyclics, Pfizer, sanofi Oncology, Seattle Genetics, and Sigma Tau Pharmaceuticals, and was an investigator for Avila, Bristol-Myers Squibb, Calistoga, Genentech, Pharmacyclics, and Talon.
Jerald P. Radich, MD, has reported that he was a consultant/advisory board member for Ariad, Bristol-Myers Squibb, Incyte, and Novartis, and an investigator for Novartis.
Istvan Redei, MD, has reported that he was a speaker for Spectrum Pharmaceuticals, and a consultant/advisory board member for Spectrum Pharmaceuticals.
Ayalew Tefferi, MD, has reported no conflicts of interest.
Julie M. Vose, MD, MBA, has reported that she was an investigator for Allos Therapeutics, Bristol-Myers Squibb, Celgene, Genentech, GlaxoSmithKline, Incyte Corporation, Millenium Pharmaceuticals, Onyx Pharmaceuticals, Pharmacyclics, S*Bio Pte. Ltd., sanofi Oncology, and U.S. Biotest, Inc.
Dannemiller, Inc.
Bernard Abrams, MD, content reviewer and Dannemiller Medical Director, has reported no conflicts of interest.
Michelle Montgomery, Dannemiller Director of Continuing Education, has reported no conflicts of interest.
Athena Education Group
Nike Gazonas, MS, has reported no conflicts of interest.
Shiva Noorchashm, has reported no conflicts of interest.
Content Review
To resolve identified/potential conflicts of interest, the educational content was fully reviewed by a physician member of the Dannemiller Clinical Content Review Committee who have no financial relationships with commercial interests. The resulting certified activity was found to provide educational content that is current, evidence-based, and commercially balanced.
Off-label Statement
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The faculty have been asked to disclose this information when presented. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, learners should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Disclaimer
The CTCA REVIEW is not an official program of ASH or ASCO, nor is it endorsed by ASH or ASCO. The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Dannemiller, Athena Education Group, or CTCA. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.
Accredited Provider:
Jointly sponsored by Dannemiller Inc. and Athena Education Group, LLC
Commercial Supporter:
These activities are supported by an educational grant from Cancer Treatment Centers of America.
Instructions:
Method of Participation
To receive continuing education credit, participants should review all program materials in their entirety, complete and submit the online post-test and evaluation, and score at least 70% on the post-test. A statement of credit will be available for printing upon successful completion.
If you have any questions relating to the accreditation for this activity, please contact cme@dannemiller.com.
If you have any other questions relating to your certificate or other issues with this activity, please contact myCME.Support@haymarketmedical.com.
Privacy Policy:
To view the Dannemiller, Inc. privacy policy, please click here.
To view the myCME privacy policy, please click here.
SYSTEM REQUIREMENTS:
WINDOWS PC SYSTEM REQUIREMENTS:
266-MHz Pentium II; Windows 98 or higher; 64 MB RAM; 800 x 600 screen resolution
set for “High Color (16-Bit)”; Macromedia Flash Player 6 or higher.
MACINTOSH® SYSTEM REQUIREMENTS:
Power Mac g3 at 300 MHz; System 8.5 or higher (excluding Mac OSX); 96 MB RAM; 20
MB minimum hard disk space available; 800 x 600 screen resolution set to “Thousands
of Colors”; Macromedia Flash Player 6 or higher.